CytoDyn Files Modified IND and Protocol for Phase
Post# of 154105

Download as PDFMarch 16, 2020 6:00am EDT
VANCOUVER, Washington, March 16, 2020 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTC.QB: CYDY), (“CytoDyn” or the “Company"

The modified protocol is a Phase 2, Randomized, Double Blind, Placebo Controlled Study to Evaluate the Efficacy and Safety of Leronlimab in Patients with Coronavirus Disease 2019 (COVID-19) and calls for 75 planned patients in up to 10 centers in the United States. Patients enrolled in the trial are expected to have a treatment window of approximately 6 weeks.
Jacob Lalezari, M.D., CytoDyn’s Interim Chief Medical Officer commented: “We appreciate the FDA’s timely input on protocol design and hope to start the treatment study in the very near future.”
Nader Pourhassan, Ph.D., president and chief executive officer of CytoDyn said: “We are pleased with the new trial design and are rapidly sending supplies of leronlimab to the clinics to begin patient treatment.”
With respect to the Company’s press release issued on March 12, 2020, management announces the following correction: Patient #1 had missed one treatment of carboplatin and will continue to be treated with carboplatin and leronlimab. Additional updates about this patient will be included in the next Company update on all cancer patients.

